LIMASSOL, Cyprus, Jan. 18, 2019 /PRNewswire-PRWeb/ -- After
successfully adding nine new contracts for difference (CFDs) on
leading Dutch stocks in early December, CySEC regulated Forex and
CFD broker, EuropeFX, has added four new cannabis stocks to their
already impressive line-up of CFDs.
These four new assets represent some of the most innovative
companies active in the development of medical cannabis related
goods or services. From the four new companies, three already have
FDA approved products on the market. The fourth, Scotts Miracle
Gro, is one of the oldest established hydroponics specialists in
North America.
CFDs on the following medicinal cannabis stocks are now
available on EuropeFX
GW Pharmaceuticals
The global leader in the development of cannabinoid-based
medicines. Cannabidiol (approved in the
United States as Epidiolex® by the Food and Drug
Administration - FDA) is in development as a treatment for certain
rare and catastrophic forms of childhood-onset epilepsy that
currently lack significant treatment options.
AbbieVie Inc.
A pharmaceutical company currently marketing an DFA approved
synthetic cannabis-based drug. Marinol alleviates nausea or
vomiting for chemotherapy patients. The drug has also been
effective with AIDS patients who have lost their appetite. While
Marinol is a breakthrough drug, it's not AbbVie's flagship product
or even their biggest seller.
Insys Therapeutics Inc
Insys aims to improve the quality of patient care by focusing on
cannabinoids and other innovative drug delivery systems to address
patient needs previously unmet. Their leadership team has
accumulated decades of experience in biotechnology,
pharmaceuticals, medical technology, life sciences, healthcare and
Fortune 500 corporate management.
Scotts Miracle Gro
With a market cap in excess of $4.5
Billion, Scotts Miracle Gro is a serious entrant into the
sector. A pioneer in the field of Hydroponics, SMG brings some
serious financial muscle and business know how to the field of
medical Cannabis. In April 2018 the
company acquired Sunlight Supply in a deal estimated a $450 Million.
Commenting on the move, EuropeFX CEO Guy
Illouz had this to say:
"The legalization of medical cannabis in the U.S. and the recent
Cannabis Act passed in Canada have
created a whole new sector for companies to operate in and for
traders to invest in. While not a "mainstream" product, quoted
companies active in the sphere of medical cannabis have to comply
with the same regulatory guidelines as other companies listed on
the same exchanges. Our clients have expressed keen interest in
this sector and as a company we are dedicated to meeting and
exceeding client expectations.
SOURCE EuropeFX